Spero Therapeutics, Inc.
SPRONasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $371,000 | $933,000 | $2.5M | $3.1M | $258,000 |
| Operating income | $6.3M | −$73.4M | $21.5M | −$42.2M | −$88.0M | −$79.1M |
| Net income | $8.6M | −$68.6M | $22.8M | −$46.4M | −$89.8M | −$78.3M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M | $153.5M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M | $21.4M |
| Equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M | $132.0M |
| EPS (diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | — |
| Shares out. | 55.9M | 53.9M | 52.6M | 32.8M | 29.5M | 20.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 50.2%
- Net margin
- 68.1%
- Return on equity
- 14.5%
- Return on assets
- 12.4%
- Return on capital (ROCE)
- 10.5%
- Liabilities / assets
- 14.4%
- Debt / equity
- 0.17×
- Book value / share
- $1.06
- Revenue growth (YoY)
- 3292.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -8.90distress
- Accruals / assets
- 30.8%high accruals
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 3 good- Altman Z″ in the distress zone
- Negative operating cash flow
- High accruals — earnings-quality risk
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Anson Funds Management LpPassive (13G)Aug 14, 2025
- Gsk PlcActivist (13D)Mar 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.6M | 2.6 | +39.6% |
| Apr 30, 2026 | 1.2M | 3.1 | +59.9% |
| Apr 15, 2026 | 737,720 | 1.4 | +21.9% |
| Mar 31, 2026 | 605,311 | 1.9 | +12.6% |
| Mar 13, 2026 | 537,411 | 1.7 | -6.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Results of operationsMar 26, 2026
- Director / officer change · Other material eventJan 30, 2026
- Other material eventDec 19, 2025
- Results of operations · Regulation FD disclosureNov 13, 2025
- Results of operations · Regulation FD disclosureAug 12, 2025
- Director / officer change · Shareholder voteJun 18, 2025
- Regulation FD disclosure · Other material eventMay 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.